Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT04780217 Active, not recruiting - Colorectal Cancer Clinical Trials

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

Start date: August 10, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1/2a Open-Label Dose Escalation and Dose Expansion Study of T3011 when Administered Intravenously as a Single Agent and in Combination with Other Therapy in Subjects with Advanced Solid Tumors

NCT ID: NCT04739527 Active, not recruiting - Ovarian Cancer Clinical Trials

Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment

ALISON
Start date: June 10, 2021
Phase: Phase 1
Study type: Interventional

Phase I study to evaluate safety and systemic immunogenicity of the DCP-001 vaccine in patients with high grade serous ovarian cancer after primary treatment.

NCT ID: NCT04731467 Active, not recruiting - Ovarian Cancer Clinical Trials

A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

Start date: March 19, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C & D) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV will be administered subsequent to CM24 and nivolumab. CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.

NCT ID: NCT04729387 Active, not recruiting - Ovarian Cancer Clinical Trials

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Start date: July 2, 2021
Phase: Phase 3
Study type: Interventional

The objective of this study is to assess the efficacy and safety of the combination of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian cancer, with no germline BRCA mutation detected.

NCT ID: NCT04724031 Active, not recruiting - Ovarian Cancer Clinical Trials

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Start date: November 1, 2019
Phase:
Study type: Observational

Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.

NCT ID: NCT04675320 Active, not recruiting - Ovarian Cancer Clinical Trials

Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors

IMMUNOPARP
Start date: July 7, 2020
Phase:
Study type: Observational

This study concerns the creation of a biological collection (blood samples) in patients with Epithelial Ovarian Cancer in in order to describe the immune response with PARP inhibitors.

NCT ID: NCT04625270 Active, not recruiting - Ovarian Cancer Clinical Trials

A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

RAMP 201
Start date: December 21, 2020
Phase: Phase 2
Study type: Interventional

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

NCT ID: NCT04608409 Active, not recruiting - Ovarian Cancer Clinical Trials

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Start date: March 17, 2021
Phase: Phase 1
Study type: Interventional

This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.

NCT ID: NCT04570839 Active, not recruiting - Ovarian Cancer Clinical Trials

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Start date: August 31, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with advanced solid tumors.

NCT ID: NCT04553133 Active, not recruiting - Breast Cancer Clinical Trials

PF-07104091 as a Single Agent and in Combination Therapy

Start date: September 16, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian cancers.